Novartis pays $150M for ArvinasArvinas' phase 3-ready prostate cancer protein degrader
PROTACsPhase 3
Preview
Source: FierceBiotech
Novartis is adding another weapon to its arsenal of oncology therapies, paying ArvinasArvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients.
The deal, which is worth up to $1.01 billion in milestones, will give Novartis global rights to ARV-766, a molecule designed to degrade wild-type and mutant androgen receptor (AR). Arvinas identified mutant degradation as a way to counter the drug resistance that can arise in patients taking AR inhibitorsAR inhibitors such as Astellas and Pfizer’s Xtandi and Johnson & Johnson’s Zytiga, but it now also sees earlier-line opportunities.
Novartis has signed up to explore the frontiers of ARV-766’s potential. The drugmaker, which is working to move its existing prostate cancer radiotherapy Pluvicto into earlier lines of therapy, has the R&D scale to tackle the opportunities that Arvinas now believes are open to ARV-766.
Arvinas indicated its interest in partnering the asset last year. Early-phase data convinced the biotech the addressable population for ARV-766 could be up to 120,000 patients with metastatic castration-sensitive and castration-resistant prostate cancer (CSPC/CRPC).
As Arvinas CEO John Houston, Ph.D., told investors on a call to discuss ARV-766 in October, CSPC is “a much bigger enterprise in terms of trial size than CRPC and ... that scenario clearly would lend itself to having a partner.” Houston added that “having a significant strategic partner for ‘766 as it moves to CSPC would be, I think, a relatively smart thing to do.”
The deal also includes the sale of ArvinasArvinas’ preclinical AR-V7 program. AR-V7 is an androgen receptor splice variant that some patients acquire. Preclinically, Arvinas’ first-generation AR asset bavdegalutamide did not degrade AR-V7.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.